Pharma Update

Lunsumio: Durable efficacy with a manageable safety profile in patients with 3L+ FL after > 2 years of follow-up Efficacy summary CR rate, n (%) ORR, n (%) Pivotal Ph II (GO29781) in 3L+ FL 06- Exploratory analysis of pivotal Ph II: Lunsumio versus last prior therapy1 IRC N=90 OS in patients with a CR at EOT from time of 1st treatment 54 (60) 104 1.01 72 (80) 0.8- mPFS, mo (95% CI) NE (26.3-NE) 0.6 Median follow-up, months 0.4 28.3 (2-38) (range) 24-mo DoCR rate, % (95% CI) 65 (39-90.5) 00 Median DoCR, months (95% CI) 44 NE (23.2-NE) Probability 04- 02- Probability mPFS (95% CI) 0.2 mPFS 12 mo (10-16 mo) NECI: NE-NE) 0.0 112 14 16 18 20 22 24 25 214 Time from first treatment (months) Roche Lunsumic - Mosunetuzumab (N=90) -Prior therapy (N=90) mPFS 24 mo (12 mo-NR) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 Time (months) • Clinically meaningful outcomes in heavily pretreated r/r FL patients with a CR rate of 60% and median DoCR not reached; 24-month DoCR rate at 65% • 24-month OS rate was 100% in patients with CR at EOT with mOS not reached • No mandatory hospitalization; manageable safety and CRS (mostly low grade and during C1) Fixed-duration treatment: 8 cycles if CR after C8; 17 cycles if PR/SD after C8 • Exploratory analysis demonstrated a 12-month improvement in mPFS with Lunsumio vs last prior therapy in the same patients despite being treated in later lines¹ • Similarly, DoCR was extended with mDoCR not reached with Lunsumio vs 15 months with last prior therapy 1Bartlett et al. ASH 2022; Sehn et al, ICML 2023; FL-follicular lymphoma; PR-partial response; SD-stable disease; DoCR-duration of complete response; ORR-overall response rate; CR=complete response; CRS-cytokine release syndrome; AE-adverse event; EOT-end of treatment; mPFS=median progression-free survival; OS-overall survival; mOS=median overall survival; C=Cycle; mDoCR=median duration of complete response; NE=not estimable 90 00

View entire presentation